F S&P 500
5,536.00 -1.00 (-0.02%) F Dow Jones
39,445.00 -81.00 (-0.20%) F Nasdaq
20,003.00 +30.75 (+0.15%) E-mini Russell 2000 Index Futur
2,036.90 -8.00 (-0.39%) Petróleo
81.38 +0.55 (+0.68%) Oro
2,318.90 -11.90 (-0.51%)
PureTech Health plc (PRTC)
PureTech Health plc
6 Tide Street
Suite 400
Boston, MA 02210
United States
617 482 2333
https://www.puretechhealth.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 90
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Bharatt M. Chowrira J.D., Ph.D. | CEO & Executive Director | 2.19M | N/D | 1965 |
| Ms. Daphne Zohar | Founder, Senior Advisor & Board Observer | 3.99M | N/D | 1971 |
| Dr. Robert S. Langer Jr., Ph.D., ScD | Co-Founder & Non-Executive Director | 135k | N/D | 1949 |
| Dr. Eric Elenko Ph.D. | Co-Founder & President | N/D | N/D | 1973 |
| Dr. David R. Elmaleh Ph.D. | Co-Founder & Senior Advisor | N/D | N/D | 1948 |
| Mr. Eric Green M.B.A. | Chief Operating Officer | N/D | N/D | N/D |
| Ms. Allison Mead Talbot | Head of Communications & Investor Relations | N/D | N/D | N/D |
| Mr. Charles Sherwood III, J.D., Ph.D. | General Counsel & Company Secretary | N/D | N/D | N/D |
| Mr. Spencer Ball | Senior Vice President of Human Resources | N/D | N/D | N/D |
| Ms. Aleksandra Filipovic M.D., Ph.D. | Head of Oncology | N/D | N/D | N/D |
Descripción
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de PureTech Health plc a partir del 1 de junio de 2024 es 9. Las puntuaciones principales son Auditoría: 10; Junta: 2; Derechos del accionista: 1; Compensación: 10.
